KeyBanc Capital Markets adjusted its price target on Inspire Medical Systems (NYSE:INSP) shares, lowering it to $234 from $236, while maintaining an Overweight rating on the stock. The revision ...

In a report released today, Brett Fishbin from KeyBanc maintained a Buy rating on Inspire Medical Systems (INSP – Research Report), with a ...

The pathophysiology of residual sleepiness in treated obstructive sleep apnoea (OSA) remains poorly understood. Animal models ...

Would you please address the dangers of untreated sleep apnea? Also, what do people do when they are unable to tolerate a CPAP (continuous positive airway pressure) ...

The global sleep apnea implants market is expected to grow from USD 317.1 million in 2023 to USD 1,158.1 million by 2033, at ...

Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”, or the “Company”), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for ...

Awareness of sleep apnea and its relatively common and effective treatment has grown over the past three decades.

Inspire Medical Systems shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 72 to 81.

Obstructive sleep apnea may have some surprising signs and symptoms of the condition. You may expect it in someone who is overweight, snores loudly, and repeatedly wakes up gasping out of sleep.

Inspire Medical Systems, Inc. (NYSE:INSP) is a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea.

Her work has appeared in Women's Health, SELF, Prevention, The Washington Post, and more. Sleep apnea impacts about 30 million American adults, making it a common sleep disorder. But while plenty ...